AMO ophthalmic viscosurgical device obtains CE Mark of Approval

Article

Abbott Medical Optics' Healon EndoCoat has received the European CE Mark of approval.

Abbott Medical Optics' Healon EndoCoat has received the European CE Mark of approval.

The viscous, low molecular ophthalmic viscosurgical device (OVD) is part of the Healon family and is currently available in Europe, Canada and New Zealand. The Food and Drug Administration (FDA) is presently reviewing the OVD for approval in the US.

Healon EndoCoat can be used as a surgical aid in cataract extraction, corneal transplantation and glaucoma filtration surgery and intraocular lens (IOL) implantation.

The properties of the approved OVD include the 25-gauge cannula delivery system with a guard. The OVD also lubricates and protects the eye during IOL implantation and can be combined with the original Healon OVD, Healon GVD OVD and Healon5 OVD.

Dr Donald Nixon, surgical director of TriMed Eye Center, Ontario, Canada, said: "The OVD plays an essential role in my cataract surgeries for overall endothelial cell preservation and patient safety."

Customers who presently order shipments of the Vitrax II OVD will be automatically updated to the Healon EndoCoat OVD.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.